Madeline Tong
Research Subjects
Research Interests
Madeline Tong has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Arushi Sharma
IQVIA Solutions Canada, Kirkland, QC H9J 2M5, Canada
1 shared publication - Daniel Rayson
Division of Medical Oncology, Department of Medicine Dalhousie University Halifax Nova Scotia Canada
1 shared publication - Guillaume Feugère
Pfizer Canada ULC, Kirkland, QC H9J 2M5, Canada
1 shared publication - Jonathan Bertin
Pfizer Canada ULC, Kirkland, QC H9J 2M5, Canada
1 shared publication - Maxim Lemelin
Pfizer Canada ULC, Kirkland, QC H9J 2M5, Canada
1 shared publication - Philip Ding
Oncology Outcomes Research Program, University of Calgary, Calgary, AB T2N 4N1, Canada
1 shared publication
Latest Publications
- Open Access
- 30 January 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (2) , 81
Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2− Women with Metastatic Breast Cancer: Results from PALCAN Study
Canadian real-world data (RWD) regarding palbociclib as a first-line therapy for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) is limited. The PALbociclib CANadian (PALCAN) study examined palbociclib utilization patterns as first-line treatment for HR+/HER2− MBC using Alberta health administrative data. The final PALCAN cohort included 472 female patients with a median age of 64 years and a median follow-up time of 22.8 months (IQR: 0.7–88.2). The median (95% CI) duration of treatment was 13.8 (12.7–15.1) months in the overall cohort (IQR: 5.6, 24.8 months), and the probability of treatment discontinuation within the first year was 45%. Aromatase inhibitors (AIs) and fulvestrant were the accompanying endocrine therapies (ETs) in 83% (N = 393) and 14% (N = 64) (15 with unknown accompanying therapy) of patients, respectively. The median duration of treatment for patients receiving an AI as an accompanying therapy was 15.1 (13.6–17.4) months and 7.9 months (5.8–12.6) for patients receiving fulvestrant, which may suggest endocrine resistance in the latter group. The PALCAN data provides insights into practice patterns and the effectiveness of palbociclib as a first-line therapy in female patients with HR+/HER2− breast cancer in the Canadian real-world setting.
- 30 January 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (2) , 81
Open AccessReal-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2− Women with Metastatic Breast Cancer: Results from PALCAN Study
Canadian real-world data (RWD) regarding palbociclib as a first-line therapy for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) is limited. The PALbociclib CANadian (PALCAN) study examined palbociclib utilization patterns as first-line treatment for HR+/HER2− MBC using Alberta health administrative data. The final PALCAN cohort included 472 female patients with a median age of 64 years and a median follow-up time of 22.8 months (IQR: 0.7–88.2). The median (95% CI) duration of treatment was 13.8 (12.7–15.1) months in the overall cohort (IQR: 5.6, 24.8 months), and the probability of treatment discontinuation within the first year was 45%. Aromatase inhibitors (AIs) and fulvestrant were the accompanying endocrine therapies (ETs) in 83% (N = 393) and 14% (N = 64) (15 with unknown accompanying therapy) of patients, respectively. The median duration of treatment for patients receiving an AI as an accompanying therapy was 15.1 (13.6–17.4) months and 7.9 months (5.8–12.6) for patients receiving fulvestrant, which may suggest endocrine resistance in the latter group. The PALCAN data provides insights into practice patterns and the effectiveness of palbociclib as a first-line therapy in female patients with HR+/HER2− breast cancer in the Canadian real-world setting.